AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18759645 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) 10, 15, 20, or 30 mg/9 h
Number of subjects: 100
Study 18759645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15977122 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based navigation system (group A)
Number of subjects: 44
Study 15977122 — intervention group
Group type: COMPARATOR
Intervention: CT-free navigation system (group B)
Number of subjects: 44
Study 15179662 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized biofeedback knee goniometer (CBG) with audiovisual feedback
Number of subjects: 25
Study 15179662 — intervention group
Group type: COMPARATOR
Intervention: Computerized biofeedback knee goniometer (CBG) with no feedback
Number of subjects: 25
Study 15179662 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of CBG readings to manual measurements
Number of subjects: 25
Study 15179662 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction assessment
Number of subjects: 25
Study 10682045 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWH)
Number of subjects: 48
Study 10682045 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 48
Study 9061172 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative intervention
Number of subjects: 75
Study 9061172 — intervention group
Group type: COMPARATOR
Intervention: Tenotomy (radicality varies)
Number of subjects: 75
Study 9061172 — intervention group
Group type: COMPARATOR
Intervention: Open neurolysis
Number of subjects: 75
Study 9061172 — intervention group
Group type: COMPARATOR
Intervention: Neurolysis for strictures on proximal side of epicondyle
Number of subjects: 75
Study 8333815 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 44
Study 8333815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 3596050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of BCG in enteric-coated capsules
Number of subjects: 29
Study 3596050 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without BCG administration
Number of subjects: 29
Study 2493409 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy‐Nitrogen Dense diet (1.5 kcal/ml; 9.4 gN/l)
Number of subjects: 118
Study 2493409 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (1.0 kcal/ml; 6.3 gN/l)
Number of subjects: 118
Study 2493409 — intervention group
Group type: COMPARATOR
Intervention: Energy Dense diet (1.5 kcal/ml; 7.8 gN/l)
Number of subjects: 118
Study 27995228 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% Chitosan gel
Number of subjects: 10
Study 27995228 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (Control)
Number of subjects: 10
Study 31675982 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-FiO2 (30% FiO2)
Number of subjects: 252
Study 31675982 — intervention group
Group type: COMPARATOR
Intervention: High-FiO2 (80% FiO2)
Number of subjects: 252
Study 28753012 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk intake
Number of subjects: 11
Study 28753012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese intake
Number of subjects: 11
Study 28753012 — intervention group
Group type: COMPARATOR
Intervention: Soy-based drink (control)
Number of subjects: 11
Study 26009576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 308
Study 26009576 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 308
Study 24247193 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: four stretching exercises of four repetitions
Number of subjects: 239
Study 24247193 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: one stretching exercise of four repetitions
Number of subjects: 239
Study 24247193 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: standard 'sit and reach' test of four trials
Number of subjects: 239
Study 24247193 — intervention group
Group type: COMPARATOR
Intervention: Group 4: no stretching performed
Number of subjects: 239
Study 21741057 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (initial dose, 0.08 mg/[kg·d] for 3 months; altered to 0.12 mg/kg or 0.04 mg/[kg·d])
Number of subjects: 20
Study 21741057 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin
Number of subjects: 20
Study 21741057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19567900 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour Your Life (online, multimedia, interactive CCBT programme)
Number of subjects: 303
Study 19567900 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) by a general practitioner
Number of subjects: 303
Study 19567900 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Colour Your Life and TAU
Number of subjects: 303
Study 16752265 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate catheter removal (group A)
Number of subjects: 96
Study 16752265 — intervention group
Group type: COMPARATOR
Intervention: Catheter removal at 6 hours (group B)
Number of subjects: 96
Study 16752265 — intervention group
Group type: COMPARATOR
Intervention: Catheter removal at 12 hours (group C)
Number of subjects: 96
Study 15133009 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-intensity warm-up (6 min)
Number of subjects: 11
Study 15133009 — intervention group
Group type: COMPARATOR
Intervention: No warm-up
Number of subjects: 11
Study 11697757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 239
Study 11697757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 239
Study 11697757 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 239
Study 11697757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 9164692 — intervention group
Group type: EXPERIMENTAL
Intervention: linopirdine (30 mg three times per day)
Number of subjects: 382
Study 9164692 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 382
Study 8127930 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 10
Study 8127930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3299395 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily for 2 weeks
Number of subjects: 18
Study 3299395 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily plus Verapamil 160 mg twice daily for 4 weeks
Number of subjects: 18
Study 3299395 — intervention group
Group type: COMPARATOR
Intervention: Verapamil 160 mg twice daily for 4 weeks
Number of subjects: 18
Study 3299395 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 18
Study 28664750 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive Ethanol Lock Therapy (ELT)
Number of subjects: 14
Study 28664750 — intervention group
Group type: COMPARATOR
Intervention: Rescue Ethanol Lock Therapy (ELT)
Number of subjects: 14
Study 26917477 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone 2.5 mg, twice a week for three months
Number of subjects: 195
Study 26917477 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone double dose first month, then twice a week for two months
Number of subjects: 195
Study 26917477 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone three times a week for three months
Number of subjects: 195
Study 26917477 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone treatment
Number of subjects: 195
Study 25569481 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric blood pressure measurement (TBPM)
Number of subjects: 57
Study 25569481 — intervention group
Group type: COMPARATOR
Intervention: Standard-care control group (C-G)
Number of subjects: 57
Study 23899190 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sedentary time (questionnaire including six sedentary activities)
Number of subjects: 83
Study 23899190 — intervention group
Group type: COMPARATOR
Intervention: Objective sedentary time (measured by Actigraph GT3X accelerometer)
Number of subjects: 83
Study 23899190 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sedentary time (using TV watching only)
Number of subjects: 83
Study 23899190 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability of the sum of six sedentary activities
Number of subjects: 83
Study 20498392 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic information regarding cognitive impairment risk (CI) after chemotherapy
Number of subjects: 365
Study 18374884 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol
Number of subjects: 0
Study 18374884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16926710 — intervention group
Group type: COMPARATOR
Intervention: High-dose alcohol preload
Number of subjects: 8
Study 16926710 — intervention group
Group type: COMPARATOR
Intervention: Alcohol preload
Number of subjects: 8
Study 16926710 — intervention group
Group type: COMPARATOR
Intervention: No alcohol preload
Number of subjects: 8
Study 12594146 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitor group (n=57)
Number of subjects: 97
Study 12594146 — intervention group
Group type: COMPARATOR
Intervention: Monitor-blind group (n=40)
Number of subjects: 97
Study 10764439 — intervention group
Group type: EXPERIMENTAL
Intervention: Special-purpose standardized pathology form
Number of subjects: 300
Study 10764439 — intervention group
Group type: COMPARATOR
Intervention: Traditional hospital pathology reports
Number of subjects: 300
Study 10764439 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained review pathologists
Number of subjects: 300
Study 8777169 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy followed by high-dose split course radiotherapy (CT + RT)
Number of subjects: 70
Study 8777169 — intervention group
Group type: COMPARATOR
Intervention: High-dose radiotherapy only (RT only)
Number of subjects: 70
Study 1725550 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 48
Study 1725550 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg/day
Number of subjects: 48
Study 1725550 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 120 mg/day diltiazem and 20 mg/day nitrendipine
Number of subjects: 48
Study 1725550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6409196 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Deprenil treatment
Number of subjects: 14
Study 6409196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30156086 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 20
Study 30156086 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 20
Study 29439732 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision training for novice occupational therapists
Number of subjects: 289
Study 29439732 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training, just encouragement)
Number of subjects: 289
Study 26773574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate (Hexabrix)
Number of subjects: 100
Study 26773574 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque)
Number of subjects: 100
Study 26773574 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with bivalirudin
Number of subjects: 100
Study 26773574 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate (Hexabrix) and Iodixanol (Visipaque)
Number of subjects: 100
Study 24176723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package promoting effective neonatal resuscitation training
Number of subjects: 184
Study 24176723 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 184
Study 22312088 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment of chronic cerebro-spinal venous insufficiency
Number of subjects: 67
Study 20233428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 103
Study 20233428 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 103
Study 18692615 — intervention group
Group type: EXPERIMENTAL
Intervention: SILCS diaphragm with 2% nonoxynol-9 (N-9) gel
Number of subjects: 15
Study 18692615 — intervention group
Group type: EXPERIMENTAL
Intervention: SILCS diaphragm with lubricant
Number of subjects: 15
Study 18692615 — intervention group
Group type: EXPERIMENTAL
Intervention: SILCS polymer spring diaphragm with 2% nonoxynol-9 (N-9) gel
Number of subjects: 15
Study 16062021 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% 20 ml bupivacaine
Number of subjects: 48
Study 16062021 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% 20 ml bupivacaine with 1 microg/kg clonidine
Number of subjects: 48
Study 16062021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12373696 — intervention group
Group type: COMPARATOR
Intervention: 8 mL of lidocaine‐bupivacaine mixture plus 0.5 mL 0.9% NaCl (group I)
Number of subjects: 60
Study 12373696 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mL of lidocaine‐bupivacaine mixture plus 0.5 mL (5 mg) atracurium (group II)
Number of subjects: 60
Study 10544340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline eye ointment administered by Village Treatment Assistants (VTAs) daily for four weeks.
Number of subjects: 280
Study 8552458 — intervention group
Group type: EXPERIMENTAL
Intervention: Original faces (unmanipulated)
Number of subjects: 50
Study 8552458 — intervention group
Group type: COMPARATOR
Intervention: Manipulated faces (various manipulations including mirror reversal, pseudo-cardioidal strain, thresholding, and elimination of internal features)
Number of subjects: 50
Study 2093019 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 or 40 mg daily
Number of subjects: 63
Study 2093019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 2093019 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg daily (maintenance)
Number of subjects: 63
Study 2093019 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg b.i.d.
Number of subjects: 63
Study 2093019 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole weekend therapy (20 mg daily on Fri, Sat, Sun)
Number of subjects: 63
Study 74302 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination schedule containing adriamycin
Number of subjects: 71
Study 74302 — intervention group
Group type: COMPARATOR
Intervention: Combination schedule without adriamycin
Number of subjects: 71
Study 74302 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 71
Study 74302 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior radiotherapy
Number of subjects: 71
Study 31712621 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbeads loaded with amino acids
Number of subjects: 0
Study 31712621 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum dot labels introduced into microbeads
Number of subjects: 0
Study 31712621 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence imaging and data analysis
Number of subjects: 0
Study 31712621 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical removal of microbeads from microwells
Number of subjects: 0
Study 31712621 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic monomer patterning
Number of subjects: 0
Study 27393428 — intervention group
Group type: COMPARATOR
Intervention: Reference product (A)
Number of subjects: 18
Study 27393428 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (B)
Number of subjects: 18
Study 24346096 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus carboplatin (nab-P/C)
Number of subjects: 0
Study 24346096 — intervention group
Group type: COMPARATOR
Intervention: sb-paclitaxel plus carboplatin (sb-P/C)
Number of subjects: 0
Study 24346096 — intervention group
Group type: COMPARATOR
Intervention: Physician assessment of peripheral neuropathy
Number of subjects: 0
Study 23895539 — intervention group
Group type: EXPERIMENTAL
Intervention: Hilotherm cooling face mask
Number of subjects: 42
Study 23895539 — intervention group
Group type: COMPARATOR
Intervention: Conventional cooling compresses
Number of subjects: 42
Study 20665254 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) applied to the posterior cerebellum
Number of subjects: 0
Study 20665254 — intervention group
Group type: COMPARATOR
Intervention: Baseline conditions (no rTMS)
Number of subjects: 0
Study 18724649 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin microsphere gel 0.04%
Number of subjects: 245
Study 18724649 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 245
Study 15917009 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet about the threat of cervical cancer from smoking and the benefits to cervical health in stopping, containing a detailed explanation of how smoking harms the cervix
Number of subjects: 330
Study 15917009 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet about the threat of cervical cancer from smoking and the benefits to cervical health in stopping, without the detailed explanation
Number of subjects: 330
Study 15917009 — intervention group
Group type: COMPARATOR
Intervention: No leaflet
Number of subjects: 330
Study 12810614 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels
Number of subjects: 601
Study 12810614 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 601
Study 12810614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen and serum amyloid A (SAA) levels
Number of subjects: 601
Study 10629345 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin
Number of subjects: 3950
Study 10629345 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 3950
Study 10629345 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no antithrombotic therapy
Number of subjects: 3950
Study 1994417 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral superparamagnetic contrast agent (800 mL ingested over approximately 2 hours)
Number of subjects: 62
Study 6823617 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapist role (highly verbal and directive)
Number of subjects: 28
Study 6823617 — intervention group
Group type: COMPARATOR
Intervention: Passive therapist role (minimally verbal or directive)
Number of subjects: 28
Study 30778865 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrovascular complications - Myocardial infarction (MI)
Number of subjects: 8713
Study 30778865 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrovascular complications - Congestive heart failure (CHF)
Number of subjects: 8713
Study 30778865 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrovascular complications - Stroke
Number of subjects: 8713
Study 30778865 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrovascular complications - Angina
Number of subjects: 8713
Study 30778865 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrovascular complications - Revascularization surgery (RS)
Number of subjects: 8713
Study 30778865 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular complications - Severe vision loss
Number of subjects: 8713
Study 30778865 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular complications - Severe pressure sensation loss
Number of subjects: 8713
Study 30778865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia (both severe and symptomatic)
Number of subjects: 8713
Study 30644302 — intervention group
Group type: EXPERIMENTAL
Intervention: arthroscopic debridement and a subsequent intra‐articular injection of autologous micro‐fragmented adipose tissue
Number of subjects: 39
Study 30644302 — intervention group
Group type: COMPARATOR
Intervention: arthroscopic debridement
Number of subjects: 39
Study 26691932 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied immediately after extraction
Number of subjects: 22
Study 26691932 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLLT applied)
Number of subjects: 22
Study 24504571 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stress
Number of subjects: 50
Study 24504571 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium stress
Number of subjects: 50
Study 24504571 — intervention group
Group type: EXPERIMENTAL
Intervention: High stress
Number of subjects: 50
Study 24504571 — intervention group
Group type: EXPERIMENTAL
Intervention: Position effect
Number of subjects: 50
Study 21692147 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hippocampal activity during successful face-name association learning
Number of subjects: 0
Study 21692147 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hippocampal activity
Number of subjects: 0
Study 21692147 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical formulations regarding medial temporal contributions
Number of subjects: 0
Study 20532650 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective self-awareness (ASA) intervention
Number of subjects: 45
Study 20532650 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 45
Study 17599424 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering low-density lipoprotein cholesterol
Number of subjects: 0
Study 17599424 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing systolic blood pressure to <140 mm Hg
Number of subjects: 0
Study 17599424 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering systolic blood pressure to <120 mm Hg
Number of subjects: 0
Study 17599424 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic control
Number of subjects: 0
Study 17599424 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy for diabetes-related dyslipidemia
Number of subjects: 0
Study 17599424 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal blood pressure control
Number of subjects: 0
Study 16291347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine growth restriction (IUGR) infants
Number of subjects: 0
Study 16291347 — intervention group
Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 0
Study 11988199 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress MRI
Number of subjects: 47